The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Clinical Roundup

Cyclin A/B RxL inhibitors restore G1–S-checkpoint in treatment of small cell lung cancer, DFCI research shows

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

A new class of drug results in cancer cell death in cancers, such as small cell lung cancer, with a disabled quality control cell cycle checkpoint known as the G1/S checkpoint, according to research gathered by the Oser Lab at Dana-Farber Cancer Institute. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Clinical Roundup

Rybrevant + Lazcluze block resistance, extend survival in first-line EGFR-mutated NSCLC, phase III trial shows

Rybrevant (amivantamab-vmjw) + Lazcluze (lazertinib) demonstrated a statistically significant and clinically meaningful overall survival improvement for patients with previously untreated locally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or L858R substitution mutations, according to data from the phase III Mariposa study.
Clinical Roundup

Tagrisso + chemo demonstrate OS benefit in EGFR-mutated NSCLC, phase III trial shows

Tagrisso (osimertinib) with the addition of pemetrexed and platinum-based chemotherapy demonstrated a statistically significant and clinically meaningful improvement in the key secondary endpoint of OS compared to Tagrisso monotherapy in the 1st-line treatment of patients with locally advanced or metastatic epidermal growth factor receptor-mutated non-small cell lung cancer. 
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account